Old Web
English
Sign In
Acemap
>
authorDetail
>
Dragana Bugarski-Kirola
Dragana Bugarski-Kirola
ACADIA Pharmaceuticals Inc.
Pimavanserin
Psychiatry
Schizophrenia
Psychology
antipsychotic treatment
4
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Comorbidities and behavioral issues.
2021
European Neuropsychopharmacology
Dragana Bugarski-Kirola
Ronald N. Marcus
Show All
Source
Cite
Save
Citations (1)
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
2021
The Lancet Psychiatry
Dragana Bugarski-Kirola
Celso Arango
Maurizio Fava
Henry Nasrallah
I-Yuan Liu
Brandon Abbs
Srdjan Stankovic
Show All
Source
Cite
Save
Citations (0)
T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
2020
Schizophrenia Bulletin
Brandon Abbs
Dragana Bugarski-Kirola
I-Yuan (Cathy) Liu
Mona Darwish
Srdjan Stankovic
Show All
Source
Cite
Save
Citations (1)
T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
2020
Schizophrenia Bulletin
Dragana Bugarski-Kirola
Rene Nunez
Ramzey Odetalla
Mohammed A Bari
István Bitter
Peter D Feldman
I-Yuan (Cathy) Liu
Srdjan Stankovic
Show All
Source
Cite
Save
Citations (1)
1